Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
NOTCH2
REST API REST API
Homo sapiens
NOTCH2 is differentially expressed in 332 experiments: 175 organism parts: bone marrow, prostate, ... (173 more);, 246 disease states: normal, glioblastoma, ... (244 more);, 119 cell types 536 cell lines 45 compound treatments and 82 other conditions.
Orthologs NOTCH2 (Gallus gallus)   Q2L697_CIOIN (Ciona intestinalis)   Notch2 (Mus musculus)   Notch2 (Rattus norvegicus)   NOTCH2 (Bos taurus)   NOTCH2 (2 of 2) (Danio rerio)   N (Drosophila melanogaster)   NOTCH2 (Xenopus laevis)   notch2 (Danio rerio)   NOTCH2 (Canis familiaris)   (Compare orthologs)
InterPro Term Notch_dom, Notch_NOD_dom, Ankyrin_rpt, Ankyrin_rpt-contain_dom, EGF_extracell, EGF, EGF_3, Notch, Notch_NODP_dom, EGF-like, Notch_2, DUF3454_notch, EGF-like_Ca-bd
Gene Ontology Term cytosol, plasma membrane, protein binding, regulation of transcription, DNA-dependent, stem cell maintenance, negative regulation of cell proliferation, cell fate determination, membrane, cell cycle arrest, extracellular region, anti-apoptosis, cell differentiation, cell growth, tissue regeneration, Notch receptor processing, hemopoiesis, induction of apoptosis, multicellular organismal development, integral to plasma membrane, nucleus, receptor activity, nervous system development, Notch signaling pathway, regulation of developmental process, integral to membrane, nucleoplasm, cell surface, endoplasmic reticulum lumen, calcium ion binding, organ morphogenesis, positive regulation of Ras protein signal transduction, bone remodeling, Golgi lumen, gene expression, ligand-regulated transcription factor activity
UniProt Accession D2WEZ3, Q13560, Q04721, Q9UFD5, F5H255, F8WA92
Gene-Disease Assocation ALAGILLE SYNDROME 2; ALGS2, HAJDU-CHENEY SYNDROME; HJCYS
Search EB-eye ENSG00000134250
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-GEOD-6573, E-GEOD-1577, E-GEOD-3526, ... (32 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-3860, E-GEOD-17482, E-GEOD-5258, E-GEOD-4525, E-GEOD-19639, ... (48 experiments)

Factor Value U/D Experiments
MCF-7
3
E-GEOD-3529, E-GEOD-20081, E-GEOD-19639
SW480
3
E-MEXP-1014, E-GEOD-2509, E-GEOD-18005
U87
2
E-MEXP-903, E-GEOD-20089
A549
2
E-GEOD-3202, E-GEOD-6013
DU145
2
E-GEOD-17482, E-GEOD-20089
K562
2
E-MTAB-37, E-GEOD-24147
530 more value(s).


Cell type

studied in E-GEOD-3920, E-GEOD-21750, E-TABM-34, E-GEOD-3998, E-GEOD-3204, ... (53 experiments)

Factor Value U/D Experiments
stromal cell
1
3
E-GEOD-1460, E-MEXP-2034, E-GEOD-10797, E-GEOD-3998
bronchial epithelial
2
E-MTAB-25, E-AFMX-5
721 B lymphoblast
2
E-AFMX-5, E-TABM-145
CD14+ monocyte
2
E-AFMX-5, E-TABM-145
embryonic stem cell
2
E-MEXP-930, E-GEOD-2248
macrophage
2
E-GEOD-22373, E-GEOD-5099
113 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-MEXP-1121, E-GEOD-1577, E-TABM-15, ... (69 experiments)

Factor Value U/D Experiments
glioblastoma
4
E-GEOD-6014, E-GEOD-4290, E-MTAB-37, E-MTAB-62
control
3
E-GEOD-16363, E-GEOD-8121, E-GEOD-16728
acute promyelocytic leukemia
3
E-MTAB-62, E-GEOD-995, E-GEOD-1729
prostate carcinoma
3
E-MTAB-62, E-MEXP-2034, E-GEOD-3868
prostate cancer
2
E-MTAB-62, E-GEOD-6919
prostate adenocarcinoma
2
E-MTAB-62, E-GEOD-3868
240 more value(s).


Compound treatment

studied in E-GEOD-5258, E-GEOD-6907, E-GEOD-5741, E-GEOD-15205, E-TABM-782, ... (23 experiments)

Factor Value U/D Experiments
none
2
6
E-GEOD-412, E-GEOD-5824, E-GEOD-20719, E-TABM-868, E-GEOD-6907, ... (8 experiments)
lipopolysaccharide
2
E-TABM-868, E-GEOD-3720
1,25-dihydroxyvitamin D3
2
1
E-GEOD-995
anti-CD3 antibody (clone:OKT3)
1
E-MEXP-1601
phenol
1
E-GEOD-6907
estradiol
1
E-GEOD-20081
39 more value(s).


A rna yield

studied in E-TABM-325

Factor Value U/D Experiments
89.02
1
1
E-TABM-325
74.51
1
1
E-TABM-325


Agent
studied in E-GEOD-19519

Biopsy tissue
studied in E-GEOD-5851

Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-GEOD-1729

Clinical history
studied in E-GEOD-22097, E-GEOD-19420, E-GEOD-19743, E-GEOD-7967, E-GEOD-21374, ... (7 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-MEXP-1251, E-GEOD-21374, ... (10 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-19743, E-GEOD-5999, E-GEOD-20033, E-GEOD-3140, E-GEOD-4667, ... (8 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-1323, E-GEOD-19743, E-GEOD-3325, E-TABM-26, E-GEOD-2509, ... (7 experiments)

double amplification
studied in E-GEOD-22601

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518, E-GEOD-3720, E-GEOD-4086

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-21589, E-GEOD-16363

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-GEOD-8023, E-GEOD-7011, E-MEXP-1482, E-GEOD-7578, E-GEOD-20847, ... (9 experiments)

Genotype
studied in E-GEOD-3494, E-GEOD-2466, E-GEOD-17476, E-GEOD-21750, E-TABM-868, ... (10 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-5681, E-MEXP-2657, E-GEOD-20540, E-GEOD-20505, E-TABM-263, ... (15 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276

Individual
studied in E-TABM-325, E-MTAB-197, E-TABM-740, E-MEXP-2069, E-TABM-15, ... (33 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-12108, E-GEOD-12254, E-MEXP-561, E-GEOD-17400, ... (6 experiments)

Injury
studied in E-GEOD-19743, E-GEOD-5372

Karyotype
studied in E-GEOD-7214, E-GEOD-22056, E-GEOD-12662

Labeling
studied in E-LGCL-5

Library source
studied in E-GEOD-19323

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-MEXP-958, E-GEOD-9171

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-1801, E-TABM-84

Organism status
studied in E-GEOD-19188

Performer
studied in E-GEOD-2004, E-LGCL-5

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-19703, E-GEOD-1309, E-GEOD-22152, E-GEOD-21750, E-GEOD-1657, ... (8 experiments)

Population
studied in E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246, ... (6 experiments)

pt
studied in E-GEOD-21653

Replicate
studied in E-GEOD-18791, E-GEOD-10896, E-GEOD-17204

Rna integrity
studied in E-TABM-325

RNAi
studied in E-MEXP-2115, E-GEOD-12438, E-MEXP-1509, E-MEXP-101, E-MEXP-548, ... (7 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743

Sex
studied in E-GEOD-1643, E-GEOD-8052, E-GEOD-7307

Stimulation
studied in E-GEOD-4883, E-GEOD-20114, E-GEOD-11886, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276, E-GEOD-2748

Transfection
studied in E-GEOD-14680

Translocation cyclin group
studied in E-GEOD-2912

Treatment
studied in E-GEOD-16837, E-GEOD-19246, E-GEOD-13818, E-GEOD-12198

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-4271

Vehicle
studied in E-GEOD-5258

Processing time: 0.475 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM